- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00844064
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-β2.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this dose-finding study is to evaluate the safety and tolerability of AP 12009. Two fixed dose-escalation schemes with predefined steps and increasing increments have been selected to determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT). At least two cycles of AP 12009 are administered intravenously in adult patients with no further acknowledged treatment options.
AP 12009 (trabedersen) is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human Transforming Growth Factor beta 2 (TGF-beta-2). The growth factor TGF-beta plays a key role in malignant progression of various tumors by inducing proliferation, invasion, metastasis, angiogenesis, and escape from immunosurveillance. In patients with pancreatic cancer, colorectal cancer, and metastatic melanoma the TGF-beta-2 overexpression is associated with disease stage, clinical prognosis, and the immunodeficient state of the patients.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Universitatsmedizin Berlin Charite
-
Halle (Saale), Germany, 06120
- Universitätsklinik und Poliklinik für Innere Medizin I
-
Heidelberg, Germany, 69115
- Hautklinik der Ruprecht-Karls-Universität Heidelberg
-
Kiel, Germany, 24105
- Universitätsklinikum Schleswig-Holstein
-
München, Germany, 81675
- Krankenhaus rechts der Isar, II. Medizinische Klinik und Poliklinik
-
Münster, Germany, 48149
- Universität Münster, Klinik und Poliklinik für Hautkrankheiten
-
Regensburg, Germany, 93042
- Klinik und Poliklinik für Innere Medizin I
-
Regensburg, Germany, 93053
- Klinik und Poliklinik für Dermatologie
-
Tübingen, Germany, 72076
- Universitäts-Hautklinik, Sektion Dermatologische Onkologie
-
Ulm, Germany, 89081
- Universitatsklinikum Ulm, Zentrum Fur Innere Medizin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent.
- Age: 18-75 years.
- Male or non-pregnant, non-lactating female.
a.Pancreatic cancer: Histologically or cytologically confirmed diagnosis, stage IVA or IVB (AJCC, 1997).
b. Melanoma: Histologically or cytologically confirmed diagnosis, stage III or IV (AJCC, UICC).
c. Colorectal cancer: Histologically or cytologically confirmed diagnosis, stage III or IV (AJCC, UICC), excluded from the last cohort.
- Patient is not or no longer amenable to established forms of therapy.
- At least one measurable lesion.
- Karnofsky performance status of at least 80%.
- Recovery from acute toxicity caused by any previous therapy.
Adequate organ function as assessed by the following laboratory values:
- Serum creatinine and urea < 2 times the upper limit of normal (ULN).
- ALT and AST < 3 ULN (in case of a liver metastasis: < 5x ULN); alkaline phosphatase < 3 ULN; and bilirubin < 2.5 mg/dL.
- Prothrombin time < 1.5 INR and PTT < 1.5 times the upper limit of normal.
- Hemoglobin > 9 g/dL.
- Platelets > 100 x 10E9/L.
- WBC > 3.0 x 10E9/L.
- Absolute Neutrophil Count (ANC) > 1.5 x 10E9/L.
Exclusion Criteria:
- Patient unable to comply with the protocol regulations.
- Pregnant or lactating female.
- Antitumor radiation therapy within 12 weeks, tumor surgery within 4 weeks or any other therapy with established antitumor effects within 2 weeks prior to study entry.
- The patient takes or is likely to need other prohibited concomitant medication. Administration of corticosteroids should be strictly avoided during the course of the study.
- Patient's participation in another clinical trial with investigational medication within 30 days prior to study entry.
- History of brain metastases. In the case of suspected brain metastases a CT scan of the skull will be performed (not mandatory in asymptomatic patients).
- Clinically significant cardiovascular abnormalities such as refractory hypertension, congestive heart failure, unstable angina, or poorly controlled arrhythmia, or a myocardial infarction within 6 months prior to treatment.
- Gastric or duodenal ulcers within 6 months before study entry or is at risk of gastrointestinal ulceration due to high consumption of NSAIDs.
- An active infection with HIV, HBV, or HCV.
- Clinically significant acute viral, bacterial, or fungal infection.
- Acute medical problems that may be considered to become an unacceptable risk, or any conditions that might be contraindications for starting study treatment.
- History of allergies to reagents used in this study.
- Drug abuse or extensive use of alcohol.
- Significant psychiatric disorders/ legal incapacity or limited legal capacity.
- History of Long QT Syndrome or QTc time ≥ 480 msec in screening/baseline ECGs. The average QTc time is to be calculated from three separate ECGs performed prior to start of infusion: two ECGs performed at Screening/Baseline (with a minimum 1-hour interval in between) and one performed within 1 hour prior to start of infusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AP 12009
|
Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles. Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week.
|
Secondary Outcome Measures
Outcome Measure |
---|
To determine the safety and tolerability of AP 12009 administered intravenously at weekly intervals and for four days every other week.
|
To assess the plasma pharmacokinetic profile of AP 12009 administered intravenously at weekly intervals and for four days every other week.
|
To establish a suitable determination method and to assess the urine pharmacokinetic profile of AP 12009 administered intravenously for four days every other week.
|
To determine the effect of AP 12009 administered intravenously at weekly intervals and for four days every other week on TGF-β2 plasma concentration levels.
|
To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Helmut Oettle, MD, Charité Berlin Campus Virchow-Klinikum
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Pancreatic Diseases
- Neuroendocrine Tumors
- Nevi and Melanomas
- Neoplasms
- Colorectal Neoplasms
- Pancreatic Neoplasms
- Melanoma
- Antineoplastic Agents
- Trabedersen
Other Study ID Numbers
- AP 12009-P001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on AP 12009
-
Isarna Therapeutics GmbHCompletedGlioblastoma | Anaplastic AstrocytomaGermany, Austria, Georgia, India, Israel, Russian Federation
-
Isarna Therapeutics GmbHTerminatedGlioblastoma | Anaplastic AstrocytomaSpain, Taiwan, Korea, Republic of, United States, Hungary, Germany, Argentina, Brazil, India, Canada, Austria, France, Mexico, Poland, Russian Federation, United Kingdom
-
Universidad Rey Juan CarlosCompletedOsteoarthritis, Knee | Musculoskeletal ManipulationsSpain
-
University of Applied Sciences of Western SwitzerlandUniversity Hospital, Geneva; University of Lausanne Hospitals; Hôpital Fribourgeois and other collaboratorsCompletedChronic Kidney Diseases | Dialysis | Chronic Kidney Diseases Associated PruritusSwitzerland
-
VA Office of Research and DevelopmentCompleted
-
Apollo Endosurgery, Inc.CompletedObesityUnited Kingdom, Australia, United States, Italy, Canada, Belgium
-
Fable Biyoteknoloji San ve Tic A.SRecruiting
-
AL-S PharmaUnknownAmyotrophic Lateral SclerosisCanada
-
AL-S PharmaRecruitingAmyotrophic Lateral SclerosisKorea, Republic of, United States, Canada, Germany, Sweden, Belgium